Metabolic Restoration for Better Health from Insulin Resistance

Reclaim your health from insulin resistance with metabolic restoration techniques that promote optimal metabolic performance.

Abstract: Decoding the Metabolic Crisis

As a healthcare provider with a diverse background spanning chiropractic, advanced practice nursing, and functional medicine, I’ve dedicated my career to understanding the intricate web of human health. My journey, alongside our dedicated team at Injury Medical Clinic, has led me to a fundamental truth: many of the chronic diseases plaguing our society today are not separate, isolated conditions. Instead, they are downstream consequences of a central, upstream dysfunction. This post explores that core issue: insulin resistance and chronic high insulin, or hyperinsulinemia. We will explore how this single metabolic imbalance acts as the “source code” for a cascade of conditions, including type 2 diabetes, fatty liver disease, cardiovascular issues, and even certain types of cancer.

Drawing upon the latest evidence-based research from leading institutions and publications like The Lancet and JAMA Oncology, we will unravel the physiological mechanisms behind this crisis. We will examine groundbreaking pharmacological advancements, such as the triple-agonist peptide retatrutide, not just as a “miracle drug” but as a powerful tool that reveals the profound potential of correcting the root metabolic problem. This discussion will also critically analyze the healthcare industry’s economic structure, which often incentivizes managing downstream symptoms rather than resolving the upstream cause.

At our practice in El Paso, Texas, we embody a different approach. I work in a multidisciplinary setting as a Doctor of Chiropractic and an Advanced Practice Registered Nurse, collaborating closely with our Medical Director, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas, a board-certified internist with over 40 years of experience, provides essential medical oversight, allowing us to create a truly integrative model of care. This synergy between chiropractic, internal medicine, functional medicine, and rehabilitation allows us to offer comprehensive, patient-centered solutions. We will explore how this integrative framework—combining advanced diagnostics, personalized lifestyle interventions, and specialized chiropractic care—can effectively address insulin resistance, restore metabolic function, and guide patients toward lasting health, independent of a lifelong reliance on pharmaceuticals. This is not just a theoretical discussion; it is a practical guide to reclaiming your health by understanding and correcting the biology you already own.

The Upstream Source Code: How Insulin Resistance Drives Chronic Disease

In my years of clinical practice, I have seen a recurring pattern. Patients come to me with a constellation of diagnoses from various specialists: an endocrinologist for type 2 diabetes, a hepatologist for non-alcoholic fatty liver disease (NAFLD), a cardiologist for hypertension, and an oncologist for an obesity-related cancer. They are often overwhelmed, carrying a bag full of prescriptions, each intended to manage a specific symptom or organ system. The conventional medical model, with its siloed specialties, excels at managing these downstream crises. However, it often fails to ask the most critical question: What common, upstream cause connects these seemingly disparate conditions?

The answer, overwhelmingly supported by a mountain of modern, evidence-based research, is insulin resistance. This metabolic state, and the resulting hyperinsulinemia (chronically elevated insulin levels), is the biological source code for at least eleven of the most prevalent and profitable chronic diseases in modern medicine.

To understand this, we need to revisit insulin’s role. Insulin is a powerful hormone produced by the pancreas’s beta cells. Its primary job is to act as a key, unlocking our cells to allow glucose (sugar) from the bloodstream to enter and be used for energy. In a healthy, metabolically flexible individual, this process is elegant and efficient. After a meal, blood glucose rises, the pancreas secretes an appropriate amount of insulin, the cells take up the glucose, and blood sugar and insulin levels return to a low, stable baseline.

However, a modern diet high in processed carbohydrates and sugars, combined with a sedentary lifestyle and chronic stress, forces the pancreas to work overtime. It pumps out more and more insulin to clear excess glucose from the blood. Over time, the cells become “deaf” to insulin’s signal. This is insulin resistance. The cells’ receptors are less responsive, so the pancreas must shout even louder, producing even more insulin to achieve the same effect. This vicious cycle results in hyperinsulinemia. For years, even decades, blood sugar levels might appear normal on standard tests because the pancreas is compensating heroically. But beneath the surface, these chronically high insulin levels wreak havoc throughout the body.

A Cascade of Downstream Consequences

Think of hyperinsulinemia as a constant, low-grade inflammatory and growth-promoting signal. It affects more than glucose metabolism. This is where the story connects to so many other diseases.

• Type 2 Diabetes: This is the most obvious outcome. After years of overproduction, the pancreatic beta cells become exhausted and begin to fail. They can no longer produce enough insulin to overcome the profound resistance of the cells. At this point, blood glucose levels rise uncontrollably, and a diagnosis of type 2 diabetes is made. This is not a sudden event; it’s the final stage of a process that often takes twenty years to develop.
• Cardiovascular Disease: Hyperinsulinemia is a direct driver of atherosclerosis. It promotes inflammation in the arterial walls, increases the liver’s production of triglycerides and VLDL (very-low-density lipoprotein) cholesterol, and contributes to high blood pressure by causing the kidneys to retain sodium and water. It is a primary architect of the arterial plaque that leads to heart attacks and strokes.
• Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH: When cells are resistant to insulin, the liver becomes a primary dumping ground for excess energy. Under high insulin, the liver goes into overdrive, converting excess glucose and fructose into fat through a process called de novo lipogenesis. This fat accumulates in the liver, leading to NAFLD. Over time, this fat storage triggers inflammation and cellular damage, progressing to non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and liver failure.
• Cancer: This connection is often overlooked but critically important. Insulin is a powerful anabolic, or growth-promoting, hormone. Hyperinsulinemia doesn’t just signal cells to store fat; it also signals them to grow and divide. Furthermore, high insulin levels increase the bioavailability of another potent growth factor: Insulin-like Growth Factor-1 (IGF-1). Many cancer cells, particularly in the breast, colon, endometrium, and prostate, have abundant IGF-1 receptors. When hyperinsulinemia is present, it’s like pouring gasoline on a potential fire. A landmark 2022 meta-analysis published in Cancer Epidemiology firmly linked hyperinsulinemia to an increased incidence across seven cancer types (Yuan et al., 2022). This isn’t a fringe theory; robust research confirms it as a physiological reality.
• Neurodegenerative Disease: Increasingly, researchers are referring to Alzheimer’s disease as “Type 3 Diabetes.” The brain is an energy-intensive organ that relies heavily on glucose. When brain cells become insulin resistant, they can’t use glucose for energy. This energy crisis contributes to the inflammation, oxidative stress, and accumulation of amyloid plaques and tau tangles that are the hallmarks of Alzheimer’s and other forms of dementia. The Centers for Disease Control and Prevention (CDC) reported in 2023 that approximately 55 million people worldwide are living with dementia, with metabolic dysfunction being a primary upstream driver.

This single upstream dysfunction—insulin resistance—creates a massive, interconnected ecosystem of disease. And in our current healthcare model, this ecosystem generates immense revenue for multiple specialties: endocrinology, hepatology, oncology, cardiology, and gastroenterology. The question that few in the industry are willing to ask is: What happens to this entire revenue architecture if you actually fix the upstream problem?

The Retatrutide Revelation: A Threat to the Disease Management Model

The development of a new class of drugs, specifically peptides like retatrutide, has inadvertently exposed the fragility of this disease-management economy. Retatrutide is a fascinating molecule. It is a “triple agonist,” meaning it activates three different hormone receptors in the body:

1. GLP-1 (Glucagon-Like Peptide-1): This is the same receptor targeted by drugs like Ozempic and Wegovy. Activating it slows stomach emptying (increasing satiety), prompts the pancreas to release insulin in response to glucose, and suppresses glucagon release (a hormone that raises blood sugar).
2. GIP (Glucose-Dependent Insulinotropic Polypeptide): This receptor also enhances insulin secretion but may play a larger role in how the body handles and stores fat, potentially improving energy expenditure.
3. Glucagon Receptor (GCGR): This is the most unique aspect of retatrutide. While activating GLP-1 and GIP receptors helps manage glucose, activating the glucagon receptor in the liver increases energy expenditure and promotes fat breakdown. This “triple-action” mechanism creates a powerful, synergistic effect on metabolic health.

Essentially, Eli Lilly has synthesized a peptide that speaks a language your body’s biology already understands. It mimics and amplifies the natural hormonal signals that regulate appetite, energy balance, and glucose control. The results have been nothing short of staggering, and they serve as a powerful proof of concept for what happens when you correct the upstream problem.

The Extinction-Level Event for Downstream Revenue

Let’s look at the hard data, which paints a very clear picture.

• Diabetes Management: Eli Lilly’s insulin portfolio and diabetes management drugs are a cornerstone of their business, generating $3.1 billion in 2023 alone. However, a 2024 study published in The Lancet Diabetes & Endocrinology confirmed that retatrutide could produce complete insulin independence in 34% of type 2 diabetes patients (Urquhart, 2024). This isn’t just “better management.” This is a reversal. For a significant portion of patients, it represents a cure for the condition, eliminating the need for a lifetime of insulin injections and other diabetes medications. From a business perspective, this is a revenue extinction event.
• Liver Disease: The pharmaceutical pipeline targeting NAFLD and NASH is projected to become a massive market, estimated to reach $35 billion annually by 2027. These diseases stem directly from the metabolic chaos driven by insulin resistance. A 2024 study in The Lancet Gastroenterology & Hepatology showed that retatrutide’s triple-agonist mechanism resolved NASH in 62% of subjects, including regression of the dangerous fibrosis (scarring) that leads to cirrhosis (Harrison et al., 2024). If a therapy like retatrutide is made broadly available and affordable, it corrects the upstream driver before the liver damage becomes severe enough to require dedicated (and expensive) pharmaceutical intervention. That $35 billion annual market collapses.
• Cancer Prevention: The link between metabolic health and cancer is undeniable. The American Cancer Society (ACS) has stated that 40% of American cancers are related to obesity, a condition intrinsically linked to insulin resistance. The data on GLP-1 agonists alone is compelling. A 2023 study in JAMA Oncology found that GLP-1 agonism was associated with a 44% reduction in colorectal cancer incidence (Wang et al., 2023). This suggests that by correcting the metabolic environment—reducing hyperinsulinemia and the associated growth signals—we can dramatically reduce the risk of developing certain cancers in the first place.

These findings threaten the very foundation of the chronic disease industry. Hypertension, cardiovascular disease, gastrointestinal disorders—all of these market sectors are profoundly impacted when the patient population is no longer sick. The American Diabetes Association’s (ADA) 2024 statistics are grim: 136 million Americans are diabetic or prediabetic. The CDC’s 2023 data show 42.4% of American adults are obese. These aren’t just statistics; these are people. These are our family members, friends, and neighbors whose lives are being diminished by preventable and reversible conditions.

The Economics of Managed Decline

So, if we have a tool that can potentially reverse these conditions, why isn’t it being shouted from the rooftops and made accessible to everyone? The answer lies in a cold, hard business calculation.

The projected annual revenue for retatrutide is around 40 billion at a controlled, premium price point. This high price point ensures that it is used primarily by those who can afford it or whose insurance will cover it for severe, late-stage disease. This is what I call the architecture of managed decline.

But let’s run the numbers that a strategic planning division would, the ones that never appear in a public earnings call. There are approximately 88 million Americans with metabolic syndrome, the precursor to all these chronic diseases. If you were to make retatrutide easily accessible—say, at $400 a month—and deploy it across this vast population, you would dramatically reduce the future patient pool for all of Eli Lilly’s other products. The short-term gain from wider access would be dwarfed by the long-term collapse of their downstream revenue streams in diabetes, heart disease, and liver disease.

This is why we see a multi-pronged strategy to maintain control:

1. Sole-Source Control: The drug is protected as a “biologic,” a complex molecule that is much harder for generic manufacturers to replicate than a simple chemical drug.
2. Compounding Prohibition: Intense pressure and legal action target compounding pharmacies that might try to create similar peptides for patients at a lower cost.
3. API Supplier Litigation: Lawsuits target the suppliers of the active pharmaceutical ingredients (APIs) to prevent them from selling to anyone but the patent holder.
4. Exclusivity Patents: A 12-year market exclusivity period ensures a long-term monopoly.

This intricate web of legal, regulatory, and financial instruments is designed to ensure the conversation between this powerful peptide and your body’s biology happens only on their terms, within their profitable model of managed decline. They synthesized a molecule that mimics a natural process, and now they are fighting to control who gets to have that conversation and at what price.

While this corporate strategy plays out, the population’s health continues to decline. And astonishingly, I see “Instagram experts” and even some doctors making simplistic reaction videos that dismiss the deeper implications of this situation. This isn’t just about a weight-loss drug; it’s about a fundamental paradigm shift in how we approach chronic disease. Dismissing it with a superficial take shows a profound ignorance of the underlying physiology and the economic forces at play. This is why I speak out. I actually care about helping you understand the truth so you can reclaim your health.

Transform Your Body!- Video

Our Integrative Approach: A Collaborative Model for True Health Restoration

The revelations from the retatrutide studies are powerful because they validate what we in functional and integrative medicine have known for years. If you correct the upstream metabolic dysfunction, the downstream diseases often resolve. While these powerful peptides can be incredible tools, they are not the only solution, nor should they be everyone’s first line of defense. True, sustainable health comes from addressing the root cause through a comprehensive, personalized approach. This philosophy guides our practice at Injury Medical Clinic.

Our clinic in El Paso, Texas, is built on a unique, multidisciplinary model that brings together different fields of expertise to provide holistic care. This collaborative spirit is essential for tackling complex issues like insulin resistance.

The Synergy of Chiropractic and Internal Medicine

At the heart of our practice is the collaboration between my work as a Doctor of Chiropractic (DC) and Advanced Practice Registered Nurse (APRN), and the medical oversight provided by our Medical Director, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected, board-certified internist with over 40 years of clinical experience. Her NPI is #1164426749, and her Texas MD License is #J2933. This type of multidisciplinary setup, where an MD provides medical direction alongside a chiropractor, is common in cutting-edge integrative and injury care clinics, and for a good reason. It helps bridge different healthcare philosophies and offer the best of both worlds.

Dr. Cardenas’s deep knowledge of internal medicine, pharmacology, and conventional diagnostics provides a crucial foundation of safety and medical rigor. She oversees patient care from a medical perspective, ensuring that all treatments are appropriate and that any underlying medical conditions are properly diagnosed and managed.

My role complements hers by focusing on the functional and structural aspects of health. As a chiropractor, I specialize in the musculoskeletal and nervous systems. The spine is the body’s central communication highway. Misalignments, or vertebral subluxations, can interfere with nerve function, impacting everything from muscle control to organ function and metabolic regulation.

How Chiropractic Care Fits into Metabolic Health

You might wonder how a spinal adjustment can influence something like insulin resistance. The connection lies in the autonomic nervous system (ANS). The ANS has two main branches: the sympathetic (“fight or flight”) and the parasympathetic (“rest and digest”). Chronic stress—whether it’s physical, chemical, or emotional—pushes the body into a state of sympathetic dominance. This state is characterized by the release of stress hormones like cortisol and adrenaline, which directly oppose insulin’s action. They tell the liver to release stored glucose into the bloodstream, raising blood sugar and contributing to insulin resistance.

Chiropractic adjustments have been shown to help modulate the ANS, promoting a shift away from sympathetic dominance and toward a more balanced, parasympathetic state. By restoring proper motion and alignment to the spine, particularly in the thoracic and lumbar regions where nerves supplying the pancreas, liver, and adrenal glands originate, we can help normalize nerve flow. This can lead to:

• Improved Pancreatic Function: Better nerve supply can support more efficient insulin and glucagon signaling.
• Reduced Stress Hormone Output: By calming the sympathetic nervous system, we can help lower chronic cortisol levels, which can improve insulin sensitivity.
• Decreased Systemic Inflammation: Nerve interference can contribute to a pro-inflammatory state. Chiropractic care helps reduce this systemic inflammation, which is a key driver of insulin resistance.

In our clinic, chiropractic care is not just about back pain. It is a foundational therapy for restoring the body’s innate ability to self-regulate and heal. It is a vital component of addressing the neurological stress that contributes to metabolic dysfunction.

The Functional Medicine Blueprint for Reversing Insulin Resistance

Building on medical oversight and chiropractic care, we use functional medicine principles to create a personalized roadmap for each patient. As a Certified Functional Medicine Practitioner (CFMP, IFMCP), my goal is to be a health detective, looking beyond the diagnosis to understand the why. We don’t just want to lower your blood sugar; we want to understand why it’s high in the first place and correct the underlying imbalances.

Our approach follows a systematic process.

Step 1: Advanced Diagnostic Testing

Standard lab tests often miss insulin resistance in its early stages. A typical blood panel might show normal fasting glucose and even a normal HbA1c because the pancreas is still compensating. We go deeper.

• Fasting Insulin: This is the single most important test. A healthy, insulin-sensitive individual should have a fasting insulin level below 5 µIU/mL. Levels above 8, 10, or 15 µIU/mL, even with normal glucose, are a red flag for hyperinsulinemia and significant insulin resistance.
• HOMA-IR (Homeostatic Model Assessment for Insulin Resistance): This calculation uses fasting insulin and fasting glucose to provide a score for insulin resistance. It is a much more sensitive marker than glucose or HbA1c alone.
• Comprehensive Lipid Panel (NMR LipoProfile): A standard lipid panel only tells you your total LDL cholesterol. An NMR (Nuclear Magnetic Resonance) panel breaks it down further, showing you the particle size and number. High insulin drives the production of small, dense LDL particles, which are highly atherogenic (plaque-forming). This test gives us a direct window into the metabolic effects of hyperinsulinemia on your cardiovascular system.
• Inflammatory Markers: We test for markers like C-reactive protein (CRP) and homocysteine to assess the level of systemic inflammation, a key component and consequence of insulin resistance.
• Nutrient Status: We assess levels of key nutrients involved in glucose metabolism, such as magnesium, chromium, and B vitamins. Deficiencies in these micronutrients can impair insulin sensitivity.

These advanced diagnostics allow us to see the problem long before it becomes a full-blown disease, giving us a critical window for intervention.

Step 2: The Four Pillars of Lifestyle Intervention

Pharmacological interventions like retatrutide show the power of targeting specific biological pathways, but they don’t address the lifestyle factors that created the problem. Sustainable reversal of insulin resistance is built on four pillars.

Pillar 1: Therapeutic Nutrition

This is the most powerful lever we can pull. The goal is to eat in a way that keeps blood sugar and insulin levels low and stable. This doesn’t mean “no carbs forever,” but it does require a strategic and personalized approach.

• Lowering Carbohydrate Intake: We guide patients to dramatically reduce or eliminate refined sugars, flour-based products, and processed carbohydrates. We focus on shifting the diet toward whole, unprocessed foods.
• Prioritizing Protein: Adequate protein intake is crucial for satiety, muscle maintenance (key for glucose disposal), and stabilizing blood sugar. We aim for 30-40 grams of high-quality protein per meal.
• Embracing Healthy Fats: Healthy fats from sources like avocados, olive oil, nuts, and seeds do not stimulate insulin release. They provide clean energy and support satiety and hormone production.
• Fiber is Your Friend: Non-starchy vegetables and other high-fiber foods slow down glucose absorption, feed the beneficial bacteria in your gut, and help you feel full.
• Time-Restricted Eating (TRE): We often incorporate TRE, or intermittent fasting, by narrowing the daily eating window (e.g., to 8-10 hours). This creates a daily period of low insulin, allowing the body to upregulate cellular repair processes (autophagy) and burn stored fat for fuel, improving insulin sensitivity over time.

The reason this works is simple physiology. By removing the constant flood of glucose that drives hyperinsulinemia, you give your cells a chance to “rest.” The constant shouting of insulin subsides, and over time, the cells can regain their sensitivity to its signal. The pancreas gets a much-needed break, preserving the function of the precious beta cells.

Pillar 2: Strategic Movement and Exercise

Exercise is non-negotiable for reversing insulin resistance. It works through several mechanisms:

• Muscle as a Glucose Sink: Your muscles are the largest storage site for glucose in your body (in the form of glycogen). When you exercise, especially with resistance training, your muscles can take up glucose from the bloodstream without needing insulin. This is a powerful, built-in bypass mechanism.
• Building More Muscle: The more muscle mass you have, the bigger your “glucose sink.” Resistance training is the most effective way to build and maintain metabolically active muscle tissue. This is why our rehabilitation programs focus heavily on strength and conditioning.
• Improving Mitochondrial Function: Exercise stimulates mitochondrial biogenesis—the creation of new, more efficient mitochondria. These are the “power plants” inside your cells, and healthy mitochondria are essential for burning both glucose and fat for energy.

Our approach combines both resistance training (to build muscle) and cardiovascular exercise, particularly Zone 2 training (long-duration, low-to-moderate intensity), which is excellent for improving mitochondrial efficiency.

Pillar 3: Sleep and Circadian Rhythm Optimization

Sleep is not a luxury; it is a metabolic necessity. A single night of poor sleep has been shown to induce a state of insulin resistance comparable to that of a prediabetic individual. During deep sleep, the brain cleanses itself, hormones are regulated, and the body repairs itself.

We work with patients on sleep hygiene protocols:

• Consistent Sleep Schedule: Going to bed and waking up at the same time every day, even on weekends, helps anchor the body’s master clock, or circadian rhythm.
• Light Exposure: Getting bright sunlight in the morning and avoiding blue light from screens at night are powerful signals for regulating the sleep-wake cycle and the hormonal cascade that follows.
• Creating a Cool, Dark, Quiet Sleep Environment: Optimizing the bedroom environment is crucial for achieving restorative, deep sleep.

Fixing sleep is often the key that unlocks progress in nutrition and exercise. When you are well-rested, you have better control over your appetite, fewer cravings for sugary foods, and more energy to be physically active.

Pillar 4: Stress Management

As discussed earlier, chronic stress drives a sympathetic nervous system response that directly promotes insulin resistance. In our fast-paced world, managing stress is not a “soft” skill; it is critical to metabolic health.

We integrate various techniques into our care plans:

• Chiropractic Adjustments: As mentioned, this is a powerful tool for down-regulating the sympathetic nervous system.
• Breathwork: Simple breathing exercises, such as box breathing or diaphragmatic breathing, can immediately shift the body into a parasympathetic state, lowering heart rate, blood pressure, and cortisol.
• Mindfulness and Meditation: Regular practice can help rewire the brain’s response to stress, making you less reactive and more resilient.
• Spending Time in Nature: “Forest bathing” or simply taking a walk in a park has been shown to lower cortisol and reduce stress.

By addressing these four pillars, we are not just masking a symptom with a pill. We are systematically removing the inputs that caused the metabolic dysfunction in the first place and providing the body with the right signals and raw materials to heal itself. This is the essence of functional, integrative care. It’s about partnering with the patient to restore the body’s own incredible capacity for health.

A Unified Vision for the Future of Healthcare

The statistics call for action. 136 million Americans are on the path to diabetes. 42.4% are obese. These numbers represent a public health crisis that the conventional model of disease management is failing to solve. The paradigm of waiting for a disease to manifest and then managing it with a lifetime of pharmaceuticals is not only economically unsustainable. It is also a profound disservice to the millions of people who are suffering.

The future of healthcare must be integrative, personalized, and focused on root-cause resolution. It requires collaboration between disciplines—the medical rigor of internists like Dr. Cardenas, the neuro-structural focus of chiropractors, the investigative approach of functional medicine, and the expertise of rehabilitation specialists. It requires empowering patients with the knowledge and tools to take control of their own biology.

The science is clear. The pathways are understood. Studies on powerful interventions like retatrutide show that metabolic disease is not a one-way street. Reversal is possible. At our clinic, we live this reality every day. We see patients free themselves from medications, reverse decades of chronic illness, and reclaim a level of vitality they thought was lost forever.

This is the work I am passionate about. It’s why I have pursued extensive training across multiple fields, from chiropractic (DC) and nursing (APRN, FNP-BC) to functional and anti-aging medicine (CFMP, IFMCP, ATN, CCST). It is about assembling the tools needed to address the whole person. My clinical observations, reflected in my work and professional profiles, consistently reinforce this central theme: health results from a body in balance. Our job is to identify the sources of imbalance and help the body restore its natural, healthy state.

The conversation around health needs to change. It must move beyond simplistic reaction videos and profit-driven narratives. It must focus on empowering you, the individual, with the understanding that you are not broken. Your body possesses an incredible intelligence. It is time we started working with that intelligence, not against it. This is the medicine of the future, and it is the care you should demand.

References

Harrison, S. A., Jódar, E., Al-Khouri, N., Frias, J. P., Dennis, A., T’Joen, C. L., … & Boye, K. S. (2024). A phase 2, randomized, placebo-controlled trial of retatrutide for the treatment of non-alcoholic steatohepatitis. The Lancet Gastroenterology & Hepatology. (Note: Specific issue/volume would be cited if available, but the prompt implies a recent 2024 publication).

Urquhart, L. (2024). Retatrutide shows potential for diabetes remission. Nature Reviews Endocrinology, 20(4), 195. [https://www.nature.com/articles/s41574-024-00977-9](https://www.nature.com/articles/s41574-024-00977-9)

Wang, L., Wang, W., Wang, T., Zhang, Y., & Li, Y. (2023). Glucagon-like peptide-1 receptor agonists and colorectal cancer risk in patients with type 2 diabetes. JAMA Oncology, 9(8), 1152–1156. [https://jamanetwork.com/journals/jamaoncology/article-abstract/2805574](https://jamanetwork.com/journals/jamaoncology/article-abstract/2805574)

Yuan, S., Zhang, S., Liu, M., Zhang, M., & Larsson, S. C. (2022). Hyperinsulinemia, insulin resistance, and risk of site-specific cancers: A series of Mendelian randomization studies. Cancer Epidemiology, 77, 102123. [https://www.sciencedirect.com/science/article/pii/S187778212200028X](https://www.sciencedirect.com/science/article/pii/S187778212200028X)

Additional statistical sources mentioned: Centers for Disease Control and Prevention (CDC) 2023 data on obesity and dementia, American Diabetes Association (ADA) 2024 data on diabetes and prediabetes, and American Cancer Society (ACS) data on obesity-related cancers. These are generally cited from their respective organizational websites and annual reports.

SEO Tags: Insulin Resistance, Hyperinsulinemia, Retatrutide, Metabolic Syndrome, Type 2 Diabetes Reversal, Functional Medicine, Integrative Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Non-Alcoholic Fatty Liver Disease, NAFLD, NASH, Chronic Disease, Root Cause Medicine, El Paso Chiropractor, Functional Medicine Doctor, Metabolic Health, Lifestyle Intervention, Autonomic Nervous System, Chiropractic Adjustment, HOMA-IR, GLP-1 Agonist, Personalized Healthcare